Regor Enters into a Definitive Purchase Agreement for Genentech to Acquire Regor’s Portfolio of next-generation CDK inhibitors for the Treatment of Breast Cancer

Genentech will acquire Regor’s next-generation CDK inhibitors for an upfront payment of $850 million in cash. Regor is also eligible to receive additional cash payments contingent on achieving future development, regulatory and commercial milestones CAMBRIDGE, Mass., Sept. 30, 2024…